Emkay Research has assigned a target price of Rs 350 per share, implying an upside of more than 37 percent from Friday's closing level. According to the brokerage, Park's business model and lean cost structure enable it to provide quality healthcare services at accessible prices, helping drive higher volumes and better asset utilisation.!